Abstract Details

Title Diagnosis of New-Onset Pre-Diabetes in Acute Ischemic Stroke

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P06 - (-)

Poster/Presentation
Number 245

Objective

Background BACKGROUND: Recently, pre-diabetes has been found to be an independent risk factor for cardiovascular disorders and stroke. In 2010 the American Diabetes Association (ADA) published new guidelines recommending the use of Hemoglobin A1C (HbA1C for diagnosis of diabetes and pre-diabetes. Diagnosis of diabetes is often made at time of hospitalization for stroke. Less is known about identification of pre-diabetes at the time of stroke admission.

Design/Methods DESIGN/METHODS: From January 2008 to December (2009) 362 AIS patients were identified by our local stroke "Get with the Guidelines Database". A baseline NIH stroke scale, TOAST criteria and stroke risk factors were collected from a computerized algorithm and retrospective chart review. Based on the 2010 ADA Guidelines, patients with HbA1c levels in the range of 5.7 to 6.4 % were classified as pre-diabetes, patients with HbA1c > 6.5 were classified as diabetics and patients with HbA1c levels < 5.7 were classified as normo-glycemic. Frequencies and group comparisons were done using SAS 9.1.

Results RESULTS: At the time of admission, 279 ischemic stroke patients (78%) had HbA1C values collected. Thirty-four percent of patients carried a diagnosis of diabetes. Stratifying by HbA1C, 113 (31%) AIS patients were given the diagnosis of DM and 109 (30%) were given the diagnosis of pre-diabetes. From the 166 AIS patients with no diabetes history, 53% were pre-diabetics and 15% were diabetics. Patients with DM and pre-diabetes were more likely to have hypertension (p<0.001) and hyperlipidemia (p=0.05) than normo-glycemic patients. The likelihood of new onset pre-diabetes increased with age (p<0.01).

Conclusions CONCLUSIONS: Our results advocate routine HbA1C testing for diagnosis of pre-diabetes in all patients admitted for AIS. Further studies are needed to confirm our findings in larger populations.

Authors/Disclosures
Gulmohor Roy, MD PRESENTER	No disclosure on file
Branko N. Huisa, MD (The Neuron Clinic)	No disclosure on file
Jorge Kawano, MD (THE UNIVERSITY OF KANSAS HOSPITAL)	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��